동물 바이오테크놀러지 시장 : 제품 유형별, 기술별, 용도별, 최종 사용자별 - 예측(2026-2032년)

The Animal Biotechnology Market was valued at USD 33.81 billion in 2025 and is projected to grow to USD 36.49 billion in 2026, with a CAGR of 8.68%, reaching USD 60.56 billion by 2032.

A strategic orientation to animal biotechnology that frames scientific innovation, regulatory evolution, and supply chain resilience as core drivers of executive decision making

Animal biotechnology stands at an inflection point where advances in molecular tools, manufacturing platforms, and regulatory frameworks converge to redefine how animal health, nutrition, and research solutions are developed and deployed. The industry now spans recombinant proteins, vaccine innovation, precision feed additives, and diagnostics that support not only livestock productivity but also biomedical research and translational science. Investors, policy makers, and corporate leaders are increasingly focused on resilient value chains, accelerated development timelines, and technologies that reduce environmental footprint while enhancing animal welfare.

Emergent capabilities in gene editing, high-throughput sequencing, and advanced cell culture are enabling new classes of biologics and platform technologies whose downstream effects will extend across therapeutic development, diagnostic throughput, and farm-level adoption. At the same time, intensifying public scrutiny, evolving trade policies, and shifting procurement practices are prompting organizations to reassess sourcing strategies and regulatory readiness. This introduction frames the critical levers-technology, policy, supply chain, and commercial strategy-that executives must prioritize to convert scientific opportunity into sustainable competitive advantage across the animal biotechnology ecosystem.

How technological inflection points, evolving commercialization models, and regulatory adaptation are reshaping competitive dynamics in animal biotechnology

The landscape of animal biotechnology is undergoing transformative shifts driven by the maturation of platform technologies and evolving commercialization pathways. Gene editing tools and transgenic methodologies have moved from proof-of-concept stages to operational use cases that accelerate trait engineering and vaccine antigen design. Concurrently, improvements in cell culture systems-including avian, insect, and mammalian platforms-are enabling more scalable and cost-efficient biologics manufacturing that reduces dependence on legacy processes. These technological inflections are also complemented by advances in sequencing and diagnostics, where next-generation sequencing and improved PCR workflows are increasing analytic resolution and shortening time-to-result horizons.

Commercial models are also shifting: contract development and manufacturing organizations are expanding capabilities to offer end-to-end services, while partnerships between research laboratories and industry actors are becoming the norm to share risk and speed deployment. Regulatory authorities are adapting to new modalities with more iterative, science-based dialogues, while sustainability pressures are pushing firms to seek lower-emissions manufacturing footprints and alternative inputs. Together, these shifts are altering competitive dynamics and creating new pathways for organizations that can integrate platform technologies, agile regulatory strategies, and resilient supply models to capture emerging opportunities in animal biotechnology.

Understanding how 2025 tariff shifts are recalibrating supply chains, sourcing strategies, and operational risk frameworks across the animal biotechnology value chain

Tariff policy developments in the United States in 2025 are exerting cumulative effects on supply chain economics, sourcing strategies, and operational planning within the animal biotechnology sector. Increased import duties on reagents, laboratory equipment, and specialized components raise landed input costs and compress margins for manufacturers and service providers. Companies are responding by accelerating supplier diversification, securing longer-term contracts with non-U.S. vendors, and exploring near-shoring or reshoring options to mitigate exposure to tariff volatility. These changes have downstream implications for procurement cycles, inventory management, and capital allocation decisions.

Beyond immediate cost pressures, tariff-driven realignments influence strategic partnerships and R&D collaborations. Organizations that previously relied on cross-border exchanges for early-stage research materials may pivot toward domestic suppliers or broaden collaborative networks to include geographically diversified research partners. Regulatory compliance and customs processes have become more complex, increasing administrative overhead for cross-border shipments of biologics and diagnostic kits. As a result, firms are investing in supply chain visibility tools and dual-sourcing strategies to maintain continuity. In parallel, the tariff environment is prompting some stakeholders to accelerate investments in local manufacturing capacity, which can reduce tariff exposure but requires careful consideration of workforce availability, capital intensity, and regulatory approvals. Overall, the tariff landscape is driving a recalibration of risk frameworks and operational models that will influence strategic planning for the foreseeable future.

Detailed segmentation analysis revealing how product, technology, application, and end-user distinctions determine development priorities, go-to-market models, and investment focus

Segmentation dynamics reveal distinct pathways to value and operational priorities across product types, technologies, applications, and end users. Based on product type, the sector spans recombinant proteins and vaccines; recombinant proteins include antibodies, enzymes, and growth hormones, and the enzymes subset comprises lipases, phytases, and proteases, while vaccines encompass DNA vaccines, inactivated vaccines, live attenuated vaccines, and subunit vaccines. This diversity requires differentiated development strategies: antibodies prioritize specificity and manufacturing scale, enzymes emphasize thermostability and feed integration, and vaccine modalities demand tailored cold-chain and regulatory approaches.

Based on technology, the market includes cell culture, genetic engineering, and PCR and DNA sequencing; cell culture further breaks down into avian, insect, and mammalian cell culture, genetic engineering covers gene editing, gene synthesis, and transgenic technology, while PCR and DNA sequencing span next-generation sequencing, PCR kits, and Sanger sequencing. These technological axes shape capital intensity, talent requirements, and regulatory interfaces. Based on application, the landscape includes diagnostics, drug discovery, and feed additives; diagnostics subdivide into ELISA kits, lateral flow assays, and PCR-based tests, drug discovery covers lead optimization, preclinical testing, and target identification, and feed additives include carbohydrases, phytases, and proteases. Application-driven segmentation highlights where value accrues: diagnostics deliver recurrent consumable demand, drug discovery requires extended R&D investment, and feed additives emphasize agricultural integration. Based on end-user, demand is sourced from animal farms, contract research organizations, pharmaceutical companies, and research laboratories. Each end-user presents unique procurement patterns and service-level expectations, requiring vendors to align product design, regulatory support, and commercial models to end-user priorities and operational constraints.

Comparative regional intelligence demonstrating how Americas, Europe Middle East and Africa, and Asia-Pacific dynamics influence regulatory strategy, manufacturing, and adoption trajectories

Regional dynamics shape opportunity sets, regulatory contours, and adoption trajectories across the Americas, Europe Middle East and Africa, and Asia-Pacific. In the Americas, established research infrastructure and significant private investment foster rapid adoption of novel biologics and diagnostic platforms, while logistical hubs and advanced manufacturing clusters support contract development and manufacturing activity. North American regulatory dialogues increasingly emphasize harmonization and expedited pathways for innovative modalities, creating an environment where scale-up and commercial launch can proceed with greater predictability when regulatory strategies are proactively managed.

In Europe, the Middle East and Africa, regulatory diversity and complex cross-border trade arrangements require granular regulatory intelligence and adaptable supply chains. The region combines mature scientific centers with markets that are still developing capacity for advanced biologics, making partnerships and public-private initiatives particularly valuable. Policy priorities around animal welfare and sustainability often shape procurement preferences in this region. In the Asia-Pacific, a combination of rapid market growth, expanding domestic manufacturing capability, and increasing public research funding is accelerating adoption of vaccines, feed additives, and diagnostics. Local manufacturers and research institutions are scaling capabilities in cell culture and genetic engineering, and cross-border collaborations are common as firms leverage cost-competitive production while accessing large regional demand pools. Across all regions, firms that craft localized regulatory strategies and supply chain architectures will gain an edge in commercial execution.

How corporate strategies combining vertical integration, platform differentiation, and talent prioritization are determining competitive positioning in animal biotechnology

Company strategies in animal biotechnology are converging on several repeatable patterns that signal winners and pressure points across the competitive landscape. Leading actors are pursuing vertical integration and strategic partnerships to secure critical inputs, reduce time-to-market, and expand value-added service offerings. Contract development and manufacturing organizations are investing in platform flexibility to accommodate both recombinant proteins and vaccine modalities, enabling them to capture a broader share of outsourced development and production demand. At the same time, specialist technology providers are differentiating through proprietary cell lines, optimized fermentation processes, or unique sequencing and diagnostic chemistries that deliver performance advantages for specific end-users.

Investment profiles show a balance between R&D intensity for next-generation modalities and operational investments in scale, quality systems, and regulatory affairs. Talent acquisition and retention have emerged as key competitive factors, with companies prioritizing cross-disciplinary teams that combine molecular biology expertise with regulatory, manufacturing, and commercialization experience. Strategic M&A and licensing transactions are being used to access niche technologies or expand geographic reach, while alliances between academic institutions and commercial developers accelerate translational milestones. Overall, organizations that combine platform innovation with robust regulatory roadmaps and flexible manufacturing partnerships are best positioned to capture emerging opportunities across animal health, feed solutions, and diagnostic applications.

Actionable strategies for leaders to fortify supply chains, modularize manufacturing, engage regulators proactively, and accelerate platform-based innovation for commercial scalability

Industry leaders should adopt a suite of tangible actions to convert scientific capability into durable commercial advantage. First, diversify procurement and logistics by qualifying multiple suppliers across geographies, establishing strategic inventory buffers for critical reagents, and investing in supply chain visibility systems to anticipate disruptions. Second, prioritize modular manufacturing investments that allow rapid reconfiguration between recombinant proteins and vaccine production, reducing changeover time and maximizing capacity utilization. Third, commit to proactive regulatory engagement by participating in jurisdictional working groups, submitting pilot data packages early, and designing clinical and safety programs that align with evolving agency expectations.

Fourth, accelerate platform-based innovation by standardizing analytical methods, sharing validated cell lines or assay formats where permissible, and pursuing partnerships that co-fund translational milestones. Fifth, enhance commercial adoption through end-user education programs that demonstrate product efficacy, ease of use, and return on operational metrics for animal farms and research laboratories. Sixth, manage talent risk through targeted recruitment, professional development, and cross-functional governance that ensures continuity across R&D, manufacturing, and regulatory teams. Implementing these recommendations will enable organizations to mitigate near-term policy headwinds, optimize capital deployment, and build scalable operations aligned with long-term scientific and commercial objectives.

A multi-method research framework combining expert interviews, literature synthesis, patent and regulatory review, and data triangulation to ensure robust and actionable insights

This analysis is based on a multi-method research approach that integrates primary expert engagement, secondary literature synthesis, and structured data triangulation. Primary inputs included confidential interviews with senior R&D leaders, manufacturing executives, and regulatory specialists across academia, industry, and contract service providers; these interviews informed scenario development and validated emergent trends. Secondary research encompassed peer-reviewed literature, patent filings, regulatory guidance documents, and technical white papers to establish the scientific and regulatory context for technology adoption and manufacturing evolution.

Quantitative and qualitative findings were cross-checked through triangulation to reconcile divergent perspectives and to highlight consensus areas. The research process also included value-chain mapping exercises to identify critical bottlenecks in sourcing, production, and distribution, and a review of public procurement and policy developments to assess potential commercial implications. Quality assurance measures included independent peer review by domain experts, source transparency protocols, and iterative feedback loops with subject-matter specialists to ensure robustness and relevance of conclusions.

Executive conclusion summarizing how integrated scientific innovation, regulatory agility, and operational resilience will determine long-term success within animal biotechnology

In conclusion, animal biotechnology is evolving through an interplay of scientific innovation, supply chain realignment, and regulatory adaptation that together create both opportunity and complexity for market participants. Technological advances in cell culture, genetic engineering, and sequencing are unlocking new product classes and efficiencies, while tariff dynamics and regional policy shifts are forcing organizations to reassess sourcing, manufacturing, and partnership strategies. Successful players will be those that translate platform capabilities into reproducible manufacturing processes, maintain regulatory agility, and construct resilient supply networks that mitigate geopolitical and logistical risks.

Looking ahead, the ability to synthesize scientific rigor with operational excellence will determine which organizations capture sustained value. Firms that invest in modular manufacturing, cultivate diversified supplier ecosystems, and engage proactively with regulators will be better positioned to convert R&D breakthroughs into scalable products and services. The path forward requires a balance of innovation, disciplined execution, and strategic partnerships that together will drive long-term growth and impact across animal health, nutrition, and research domains.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Porter's Five Forces Analysis
• 4.4. PESTLE Analysis
• 4.5. Market Outlook
  • 4.5.1. Near-Term Market Outlook (0-2 Years)
  • 4.5.2. Medium-Term Market Outlook (3-5 Years)
  • 4.5.3. Long-Term Market Outlook (5-10 Years)
• 4.6. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Animal Biotechnology Market, by Product Type

• 8.1. Recombinant Proteins
  • 8.1.1. Antibodies
  • 8.1.2. Enzymes
    • 8.1.2.1. Lipases
    • 8.1.2.2. Phytases
    • 8.1.2.3. Proteases
  • 8.1.3. Growth Hormones
• 8.2. Vaccines
  • 8.2.1. DNA Vaccines
  • 8.2.2. Inactivated Vaccines
  • 8.2.3. Live Attenuated Vaccines
  • 8.2.4. Subunit Vaccines

9. Animal Biotechnology Market, by Technology

• 9.1. Cell Culture
  • 9.1.1. Avian Cell Culture
  • 9.1.2. Insect Cell Culture
  • 9.1.3. Mammalian Cell Culture
• 9.2. Genetic Engineering
  • 9.2.1. Gene Editing
  • 9.2.2. Gene Synthesis
  • 9.2.3. Transgenic Technology
• 9.3. PCR And DNA Sequencing
  • 9.3.1. Next-Generation Sequencing
  • 9.3.2. PCR Kits
  • 9.3.3. Sanger Sequencing

10. Animal Biotechnology Market, by Application

• 10.1. Diagnostics
  • 10.1.1. ELISA Kits
  • 10.1.2. Lateral Flow Assays
  • 10.1.3. PCR-Based Tests
• 10.2. Drug Discovery
  • 10.2.1. Lead Optimization
  • 10.2.2. Preclinical Testing
  • 10.2.3. Target Identification
• 10.3. Feed Additives
  • 10.3.1. Carbohydrases
  • 10.3.2. Phytases
  • 10.3.3. Proteases

11. Animal Biotechnology Market, by End-User

• 11.1. Animal Farms
• 11.2. Contract Research Organizations
• 11.3. Pharmaceutical Companies
• 11.4. Research Laboratories

12. Animal Biotechnology Market, by Region

• 12.1. Americas
  • 12.1.1. North America
  • 12.1.2. Latin America
• 12.2. Europe, Middle East & Africa
  • 12.2.1. Europe
  • 12.2.2. Middle East
  • 12.2.3. Africa
• 12.3. Asia-Pacific

13. Animal Biotechnology Market, by Group

• 13.1. ASEAN
• 13.2. GCC
• 13.3. European Union
• 13.4. BRICS
• 13.5. G7
• 13.6. NATO

14. Animal Biotechnology Market, by Country

• 14.1. United States
• 14.2. Canada
• 14.3. Mexico
• 14.4. Brazil
• 14.5. United Kingdom
• 14.6. Germany
• 14.7. France
• 14.8. Russia
• 14.9. Italy
• 14.10. Spain
• 14.11. China
• 14.12. India
• 14.13. Japan
• 14.14. Australia
• 14.15. South Korea

15. United States Animal Biotechnology Market

16. China Animal Biotechnology Market

17. Competitive Landscape

• 17.1. Market Concentration Analysis, 2025
  • 17.1.1. Concentration Ratio (CR)
  • 17.1.2. Herfindahl Hirschman Index (HHI)
• 17.2. Recent Developments & Impact Analysis, 2025
• 17.3. Product Portfolio Analysis, 2025
• 17.4. Benchmarking Analysis, 2025
• 17.5. Animal Genetics, Inc.
• 17.6. Bio-Rad Laboratories, Inc.
• 17.7. Biogenesis Bago S.A.
• 17.8. Boehringer Ingelheim International GmbH
• 17.9. Ceva Sante Animale S.A.
• 17.10. Dechra Pharmaceuticals plc
• 17.11. Elanco Animal Health Incorporated
• 17.12. Genus plc
• 17.13. Hendrix Genetics BV
• 17.14. HIPRA S.A.
• 17.15. IDEXX Laboratories, Inc.
• 17.16. Merck & Co., Inc.
• 17.17. Neogen Corporation
• 17.18. Phibro Animal Health Corporation
• 17.19. Recombinetics, Inc.
• 17.20. Thermo Fisher Scientific Inc.
• 17.21. Trans Ova Genetics, LC
• 17.22. Vetoquinol S.A.
• 17.23. Virbac S.A.
• 17.24. Zoetis Inc.